NeuroMetrix, Inc.
62 Fourth Avenue
Waltham
Massachusetts
02451
United States
Tel: 781-890-9989
Fax: 781-890-1556
Website: http://www.neurometrix.com/
Email: info@neurometrix.com
432 articles about NeuroMetrix, Inc.
-
Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)
5/31/2023
NeuroMetrix, Inc. (Nasdaq: NURO) noted publication of an abstract describing partial results from a NIH-funded, multi-site randomized controlled trial of Quell titled "Wireless transcutaneous electric nerve stimulation (TENS) for chemotherapy-induced peripheral neuropathy (CIPN): A proof-of-concept, placebo-controlled, randomized clinical trial (RCT)."
-
NeuroMetrix Reports Q1 2023 Financial Results
5/3/2023
NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2023.
-
NeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference Call
4/28/2023
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2023 first quarter financial results before the opening of the market on May 3, 2023.
-
NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting
3/21/2023
NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39th Annual Meeting on March 23 - 26 in Ft. Lauderdale, FL.
-
NeuroMetrix Reports Q4 and Full Year 2022 Financial Results
2/23/2023
NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2022.
-
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call
2/16/2023
NeuroMetrix, Inc. announced that it plans to issue its 2022 fourth quarter and year end financial results before the opening of the market on February 23, 2023.
-
NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy
1/23/2023
NeuroMetrix, Inc. announced the commercial availability of DPNCheck 2.0, the Company's latest point-of-care device that leverages gold-standard nerve conduction technology to detect peripheral neuropathy.
-
NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting
11/8/2022
NeuroMetrix, Inc. (Nasdaq: NURO) will introduce Quell Fibromyalgia at the American College of Rheumatology Annual Meeting, ACR Convergence 2022, on November 12 – 14 in Philadelphia, Pennsylvania.
-
NeuroMetrix Announces Strategic Launch of Quell Fibromyalgia
11/3/2022
NeuroMetrix, Inc. announced the strategic launch of its Quell® Fibromyalgia device through the Pathfinder Program.
-
NeuroMetrix Reports Q3 2022 Financial Results
10/20/2022
NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and nine-month period ended September 30, 2022.
-
NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference Call
10/12/2022
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 third quarter financial results before the opening of the market on Oct 20, 2022.
-
NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics Business
9/1/2022
NeuroMetrix, Inc. announced that it has appointed Jonathan "Breck" Harmel as National Director of Sales, Neuromodulation.
-
NeuroMetrix Reports Q2 2022 Financial Results
7/21/2022
NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and six months period ended June 30, 2022.
-
NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call
7/14/2022
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 second quarter financial results before the opening of the market on July 21, 2022.
-
NeuroMetrix Appoints Brad Fluegel to its Board of Directors
6/28/2022
NeuroMetrix, Inc. announced the appointment of Bradley M. Fluegel to its Board of Directors, effective as of July 1, 2022.
-
NeuroMetrix Reports that Quell® Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia
5/19/2022
NeuroMetrix, Inc. (Nasdaq: NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity.
-
NeuroMetrix Reports Q1 2022 Financial Results
4/26/2022
NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2022.
-
NeuroMetrix, Inc. Announces Date for First Quarter 2022 Financial Results Conference Call
4/19/2022
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 first quarter financial results before the opening of the market on April 26, 2022.
-
NeuroMetrix Reports that Quell® Wearable Neuromodulator to be Evaluated in Post-Acute COVID-19 Syndrome
2/24/2022
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell wearable neuromodulation technology will be evaluated for treatment of a fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome (PACS, or "long COVID").
-
NeuroMetrix Reports Q4 and Full Year 2021 Financial Results
1/27/2022
NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2021.